| pubmed-article:20799264 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0035452 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0020205 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C1872109 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0282461 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:20799264 | lifeskim:mentions | umls-concept:C0557806 | lld:lifeskim |
| pubmed-article:20799264 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20799264 | pubmed:dateCreated | 2011-1-5 | lld:pubmed |
| pubmed-article:20799264 | pubmed:abstractText | The American College of Rheumatology (ACR) hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to 20%, 50%, and 70% response criteria (ACR20/50/70) scores, but has not been tested in clinical trials. We performed a post hoc analysis of a phase III study of certolizumab pegol (Rheumatoid Arthritis Prevention of Structural Damage 1 [RAPID 1]) using the ACR hybrid. | lld:pubmed |
| pubmed-article:20799264 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20799264 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20799264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20799264 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20799264 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20799264 | pubmed:issn | 2151-4658 | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:StranoAA | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:KeystoneE CEC | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:WeinblattM... | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:FelsonDD | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:20799264 | pubmed:author | pubmed-author:LuijtensKK | lld:pubmed |
| pubmed-article:20799264 | pubmed:copyrightInfo | Copyright © 2011 by the American College of Rheumatology. | lld:pubmed |
| pubmed-article:20799264 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20799264 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:20799264 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20799264 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20799264 | pubmed:pagination | 128-34 | lld:pubmed |
| pubmed-article:20799264 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:meshHeading | pubmed-meshheading:20799264... | lld:pubmed |
| pubmed-article:20799264 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20799264 | pubmed:articleTitle | American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. | lld:pubmed |
| pubmed-article:20799264 | pubmed:affiliation | Karolinska Institute, Stockholm, Sweden. Ronald.van.Vollenhoven@ki.se | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| pubmed-article:20799264 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
